MacroGenics FY Conference Summary Company Overview - **Company**: MacroGenics (NasdaqGS: MGNX) - **Focus**: Development of next-generation antibody therapeutics for cancer treatment, with over 20 years of experience [2][3] Core Modalities - **Antibody-Drug Conjugates (ADCs)**: Three ADC programs in the portfolio, leveraging third-party drug linker chemistries from Synaffix and proprietary antibody engineering [2][3] - **T-cell Engagers**: Partnership with Gilead on three T-cell related constructs, including a clinical program targeting CD123 and CD3 [3] - **Dual Checkpoint Approach**: Led by the lorigerlimab program, a bispecific antibody targeting PD-1 and CTLA-4 [3] ADC Pipeline Highlights - **MGC026 (Anti-B7H3 ADC)**: - Features a novel payload (exatecan) that is 2-5 times more potent than deruxtecan, with better bystander killing effects and reduced susceptibility to multidrug resistance [8] - No evidence of interstitial lung disease (ILD) observed in clinical trials, a potential differentiator from competitors [9][10] - Targeting multiple solid tumors, including small cell lung cancer and castrate-resistant prostate cancer [12] - **MGC028 (ADAM9 ADC)**: - A second-generation ADC targeting ADAM9, with a focus on safety and efficacy based on previous learnings from a first-generation molecule [21][22] - Phase 1 data expected in the second half of 2026, targeting various solid tumors [25][26] - **MGC030**: - A first-in-class Topo 1 ADC with strong preclinical data, IND expected in Q3 2026 [30] Lorigerlimab Program - **Dual Checkpoint Inhibitor**: Blocking both PD-1 and CTLA-4, with over 300 patients dosed [35] - **Safety Profile**: Early data shows fewer adverse events compared to traditional combinations like ipilimumab and nivolumab [35] - **Current Status**: Enrollment paused due to grade 4 adverse events, including one fatality; working with the FDA to resume [37][38] Financial Position - **Cash Position**: Approximately $190 million at the end of the year, with a history of raising over $600 million in non-dilutive capital over the last 3.5 years [28] - **Partnerships**: Significant future milestone payments from partnerships, including $1.6 billion from Gilead and $540 million from Incyte [43][45] Strategic Focus - **Prioritization of Programs**: Focus on advancing ADC programs to proof-of-concept inflection points while managing cash runway effectively [28][29] - **Potential for New Partnerships**: Open to future collaborations, especially for broad utility targets [17][19] Conclusion - **Outlook for 2026**: Anticipated to be a pivotal year for MacroGenics with multiple data readouts and strategic advancements in their pipeline [49]